Gene therapy of lung cancer
Jonathan C. Daniel MD,
W. Roy Smythe MD,
Corresponding Author
Jonathan C. Daniel MD
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd—Unit 445, Houston, TX 77030. Fax: 713/794-4901.Search for more papers by this authorW. Roy Smythe MD
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Search for more papers by this authorJonathan C. Daniel MD,
W. Roy Smythe MD,
Corresponding Author
Jonathan C. Daniel MD
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd—Unit 445, Houston, TX 77030. Fax: 713/794-4901.Search for more papers by this authorW. Roy Smythe MD
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Search for more papers by this authorAbstract
It is estimated that there will be 157,200 deaths from lung cancer in 2003. Current regimens of surgery, chemotherapy and radiation have not significantly changed overall 5-year survival rates for this disease. Thanks to intensive molecular studies over the last three decades, new targets for treatment have been identified, including replacement of tumor suppressor genes, prevention of angiogenesis and tumor growth, and regulation of programmed cell death. Promising advances have been made but obstacles still abound before effective use of these strategies at the patient bedside can occur. One area of concentration lies in developing more accurate and complete delivery of the therapeutic constructs. In the evolution of gene therapy approaches, from beginning theory to translational research, investigators in thoracic malignancies have played a leading role, utilizing a number of methods and delivery vehicles. The objective of this review is to discuss some of the major molecular targets available for manipulation in lung cancer, describe vectors and techniques currently used by thoracic researchers to deliver therapy, and provide the p53 model as an example of progression from bench research to clinical treatment. Semin. Surg. Oncol. 21:196–204, 2003. © 2003 Wiley-Liss, Inc.
REFERENCES
- 1 Lederberg J: “ DNA breakthrough points way to therapy by virus.” Washington Post; 13 January 1968.
- 2 Lederberg J: An early history of gene transfer and therapy. Hum Gene Ther 1994; 5: 469–480.
- 3 Culver KW, Osborne WR, Miller AD, et al: Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant Proc 1991; 23: 170–171.
- 4 American Cancer Society: Cancer facts and figures 2003. Website. http://www.cancer.org.
- 5 LAG Ries, MP Eisner, CL Kosary, et al. (eds): “ SEER Cancer Statistics Review, 1975-2000.” Bethesda, MD: National Cancer Institute; 2003.
- 6 Hung J, Kishimoto Y, Sugio K, et al: Allele specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995; 273: 558–563.
- 7 Mori N, Yokota J, Oshimura M, et al: Concordant deletions of chromosome 3p and loss of heterozygosity for chromosomes 13 and 17 in small cell lung carcinoma. Cancer Res 1989; 49: 5130–5135.
- 8 Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 1998; 16: 1207–1217.
- 9 Chiba I, Takahashi T, Nau MM, et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990; 5: 1603–1610.
- 10 Takahashi T, Nau MM, Chiba I, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246(4929): 491–494.
- 11 Craig C, Kim M, Ohri E, et al: Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 1998; 16: 265–272.
- 12 Joshi US, Chen YQ, Kalemkerian GP, et al: Inhibition of tumor cell growth by p21 WAF1 adenoviral gene transfer in lung cancer. Cancer Gene Ther 1998; 5: 183–191.
- 13 Naruse I, Hoshino H, Dobashi K, et al: Over-expression of p27kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int J Cancer 2000; 88: 377–383.
- 14 Antelman D, Machemer T, Huyghe BG, et al: Inhibition of tumor cell proliferation in vitro and in vivo by exogenous p110RB, the retinoblastoma tumor suppressor protein. Oncogene 1995; 10: 697–704.
- 15 Sozzi G, Tornielli S, Tagliabue E, et al: Absence of FHIT protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57: 5207–5212.
- 16 Tseng JE, Kemp BL, Khuri FR, et al: Loss of FHIT is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999; 59: 4798–4803.
- 17 Ji L, Fang B, Yen N, et al: Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59: 3333–3339.
- 18 Mhashilkar AM, Schrock RD, Hindi M, et al: Melanoma differentiation associated gene -7 (MDA-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001; 4: 271–282.
- 19 Saeki T, Mhasilkar AM, Swanson X, et al: Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002; 21: 4558–4566.
- 20 Fontanini G, Lucchi M, Vignati S, et al: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881–886.
- 21 Fontanini G, Vignati S, Boldrini L, et al: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3: 861–865.
- 22 Giatromanolaki A, Koukourakis MI, Kakolyris S, et al: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998; 4: 3017–3024.
- 23 Devore RF, Fehrenbacker RS, Herbst RS, et al: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLS [Abstract]. Proc Am Soc Clin Oncol 2000; 19: 485a.
- 24 Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219(4587): 983–985.
- 25 Zebrowski BK, Yano S, Wenbiao L, et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 5: 3364–3368.
- 26 Selvaggi G, Scagliotti GV, Torri V, et al: HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer 2002; 94: 2669–2674.
- 27 Kern JA, Schwartz DA, Nordberg JE, et al: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184–5187.
- 28
Casalini P,
Menard S,
Malandrin SM, et al:
Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbb2 antisense expression.
Int J Cancer
1997;
72:
631–636.
10.1002/(SICI)1097-0215(19970807)72:4<631::AID-IJC14>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 29
Fang K,
Chen MH:
Transfection of anti-sense complementary DNA of human epidermal growth factor receptor attenuates the proliferation of human non-small cell lung cancer cells.
Int J Cancer
1999;
81:
471–478.
10.1002/(SICI)1097-0215(19990505)81:3<471::AID-IJC23>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 30 Azzoli CG, Krug LM, Miller VA, et al: Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 2002; 29(1 Suppl 4): 59–65.
- 31 Slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561–565.
- 32 Mukhopadhyay T, Tainskym Cavender AC, Roth JA: Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51: 1744–1748.
- 33 Alemany R, Ruan S, Kataoka M, et al: Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther 1996; 3: 296–301.
- 34 Zhang Y, Nemunaitis J, Tong A: Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. Mol Biotechnol 2000; 15: 39–49.
- 35 Reed J: Double identity for proteins of the Bcl-2 family. Nature 1997; 387(6356): 773–776.
- 36 Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non small-cell carcinoma. N Engl J Med 1993; 329: 690–694.
- 37 Soini Y, Kinnula V, Kaarteenhaho WR, et al: Apoptosis and expression of apoptosis—regulating proteins bcl-2, mcl-1, bclx and bax in malignant mesothelioma. Clin Cancer Res 1999; 5: 3508–3515.
- 38
Leech SH,
Olie RA,
Gautschi O, et al:
Induction of apoptosis in lung-cancer cells following bcl-xl anti-sense treatment.
Int J Cancer
2000;
86:
570–576.
10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 39 Gautschi O, Tschopp S, Olie RA, et al: Activity of a novel bcl- 2/bcl-xl bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001; 93: 463–471.
- 40 Smythe WR, Mohuiddin I, Ozvaran M, Cao X: Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002; 123: 1191–1198.
- 41 Mohiuddin I, Cao X, Fang B, et al: Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 2001; 8: 547–554.
- 42 Pataer A, Smythe WR, Yu R, et al: Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001; 121: 61–67.
- 43 Kagawa S, He C, Gu J, et al: Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 6: 3330–3338.
- 44 Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276–5281.
- 45 Smythe WR: Prodrug/Drug sensitivity gene therapy: current status. Curr Oncol Rep 2000; 2: 17–22.
- 46 Culver KW, Ram Z, Wallbridge S, et al: In vivo gene transfer with retroviral vector producer cells for the treatment of experimental brain tumors. Science 1992; 256(5063): 1550–1552.
- 47 Smythe WR, Hwang HC, Amin KM, et al: Use of recombinant adenovirus to transfer the herpes simplex thymidine kinase gene (HSVtk) to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994; 54: 2055–2059.
- 48 Smythe WR, Hwang HC, Elshami AA, et al: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222: 78–86.
- 49 Hwang HC, Smythe WR, Elshami AA, et al: Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995; 13: 7–16.
- 50 Sterman DH, Treat J, Litzky LA, et al: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083–1092.
- 51 Wiewrodt R, Kunjlata A, Kiefer M, et al: Adenovirus-mediated gene transfer of enhanced herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 2003; 10: 353–364.
- 52 Kurdow R, Boehle AS, Haye S, et al: Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer. Ann Thorac Surg 2002; 73: 905–910.
- 53 Gautum A, Densmore CL, Waldrep JC: Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther 2000; 2: 318–323.
- 54 Kubba S, Adak S, Shiller J, et al: Phase I trial of Adenovirus p53 in bronchioalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage [Abstract]. Proc Am Soc Clin Oncol 2000; 19: 487a.
- 55 Osaki T, Hanagiri T, Nakanishi R, et al: Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer. Chest 1999; 115: 1424–1428.
- 56 Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–256.
- 57 Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239–4242.
- 58 Thomas C, Ehrhardt A, Kay M: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346–358.
- 59 Burns JC, Friedmann T, Driever W, et al: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammallian cell. Proc Natl Acad Sci USA 1993; 90: 8033–8037.
- 60 Morsy MA, Caskey CT: Expanded-capacity adenoviral vectors—the helper-dependent vectors. Mol Med Today 1999; 5: 18–24.
- 61 Fisher KD, Stallwood Y, Green NK, et al: Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther 2001; 8: 341–348.
- 62 Hemminki A, Kanerva A, Liu B, et al: Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003; 63: 847–853.
- 63 Chesnoy S, Huang L: Structure and function of lipid-DNA complexes for gene delivery. Annu Rev Biophys Biomol Struct 2000; 29: 27–47.
- 64 Mahato RI, Kawabata K, Takakura Y, Hashida M: In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target 1995; 3: 149–157.
- 65 Templeton NS, Lasic DD, Frederik PM, et al: Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997; 15: 547–652.
- 66 Ramesh R, Saeki T, Templeton NS, et al: Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 2001; 3: 337–350.
- 67 Tousignant JD, Gates AL, Ingram LA, et al: Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 2000; 11: 2493–2513.
- 68 Tan Y, Li S, Pitt BR, Huang L: The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999; 10: 2153–2161.
- 69 Zou Y, Zong G, Ling YH, Perez-Soler R: Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther 2000; 7: 683–696.
- 70 Chen J, Wu X, Lin J, Levine AJ: Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996; 16: 2445–2452.
- 71 Suzuki H, Takahashi T, Kuoishi T, et al: p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992; 52: 734–736.
- 72 Fugiwara T, Cai DW, Georges RN, et al: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458–1462.
- 73 Zhang WW, Fang X, Mazur W, et al: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5–13.
- 74 Swisher SG, Roth JA: Adenoviral p53 gene therapy strategies in non-small cell lung cancer. In H Choy (ed): “ Chemoradiation in cancer therapy.” New Jersey: Humana Press; 2002; p. 351–360.
- 75 Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 transfers to tumors of patients with lung cancer. Nat Med 1996; 2: 985–991.
- 76 Shuler M, Rochlitz C, Horowitz JA, et al: A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998; 9: 2075–2082.
- 77 Swisher SG, Roth J, Nemunaitis J, et al: Adenovirus-Mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91: 763–771.
- 78 Lowe SW, Ruley HE, Jacks T, Housman DE: P53–dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–967.
- 79 Rusch V, Klimstra D, Venkatraman E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038–5042.
- 80 Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2297–2291.
- 81 Nemunaitis J, Swisher SG, Timmons T, et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609–622.
- 82 Shuler M, Herrmann R, Jacques LP, et al: Adenovirus-Mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: results of a multicenter Phase II study. J Clin Oncol 2001; 19: 1750–1758.
- 83 Swisher SG, Roth JA, Komaki R, et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93–101.
